About Millendo Therapeutics
Millendo Therapeutics is a company based in Ann Arbor (United States) founded in 2012. Millendo Therapeutics has raised $102.77 million across 5 funding rounds from investors including University of Michigan, Frazier Healthcare Partners and NEA. The company has 30 employees as of December 31, 2022. Millendo Therapeutics has completed 1 acquisition, including Alizé Pharma. Millendo Therapeutics operates in a competitive market with competitors including BeiGene, Moderna, Incyte, Regeneron Pharmaceuticals and Mereo BioPharma, among others.
- Headquarter Ann Arbor, United States
- Employees 30 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Atterocor Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$102.77 M (USD)
in 5 rounds
-
Latest Funding Round
$62 M (USD), Series B
Jan 04, 2016
-
Investors
University of Michigan
& 9 more
-
Employee Count
30
as on Dec 31, 2022
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Millendo Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Millendo Therapeutics
Millendo Therapeutics has successfully raised a total of $102.77M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $62 million completed in January 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Millendo Therapeutics
Millendo Therapeutics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include University of Michigan, Frazier Healthcare Partners and NEA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked | |
|
Venture capital fund backed incubator focused on the healthcare startups
|
Locked | Locked | Locked | |
|
Venture capital is directed toward healthcare companies by Longwood Fund.
|
Locked | Locked | Locked |
Investor details for Millendo Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Millendo Therapeutics
Millendo Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Alizé Pharma.
Investment portfolio details for Millendo Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Develop drugs, proteins and peptides for the treatment of metabolic and rare diseases
|
Locked | Locked | 2007 | Locked |
Complete acquisition details for Millendo Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Millendo Therapeutics
Detailed financials for Millendo Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Millendo Therapeutics Comparisons
Peer comparison for Millendo Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Millendo Therapeutics
Millendo Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Moderna, Incyte, Regeneron Pharmaceuticals and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Antibodies are developed for treating cancer, eye, and inflammatory diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
ALX Oncology is focused on advancing cancer treatment therapies.
|
Detailed competitors of Millendo Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Millendo Therapeutics
Complete news archive for Millendo Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Millendo Therapeutics
Millendo Therapeutics was founded in 2012.
Millendo Therapeutics is headquartered in Ann Arbor, United States. It is registered at Ann Arbor, Michigan, United States.
Millendo Therapeutics is a funded company, having raised a total of $102.77M across 5 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Millendo Therapeutics is 30.
Millendo Therapeutics was founded in 2012 in Ann Arbor, United States, within the biotechnology sector. Focus is placed on immune-mediated targeted therapies for cancer. The product pipeline is composed of TPST-1120, a PPARα antagonist used in hepatocellular carcinoma, cholangiocarcinoma, and renal cell carcinoma; TPST-1495, applied to multiple solid tumors; and a TREX-1 inhibitor. Operations center on advancing these candidates through clinical development.
Millendo Therapeutics's top competitors include Moderna, BeiGene and Strand Therapeutics.
Millendo Therapeutics has made 1 acquisition, including Alizé Pharma.
Millendo Therapeutics has 10 investors. Key investors include University of Michigan, Frazier Healthcare Partners, NEA, 5AM Ventures, and Renaissance Venture Capital Fund.